Publications by authors named "Hanneke Voorneveld"
Article Synopsis
- The study analyzed the effects of switching adult patients with rheumatoid arthritis, psoriatic arthritis, and spondyloarthritis from the reference drug adalimumab (Humira®) to its biosimilar (Amgevita®).
- Out of 603 patients, over 93% successfully transitioned without significant changes in disease activity or safety, confirming the equivalence of the two treatments.
- Some patients experienced nocebo effects, highlighting the importance of addressing patient perceptions to optimize treatment outcomes and maintain cost benefits of using biosimilars.
Objective: Making a differential diagnosis of psoriatic arthritis (PsA) is not straightforward. This is partly because of its heterogeneous presentation and partly because many patients with PsA are initially diagnosed with psoriasis and treated in primary care or by dermatologists, with referral to rheumatologists being delayed. Once diagnosed, optimal disease control requires frequent specialist monitoring, adjustment or switching of therapies, and management of comorbidities and concomitant diseases, as well as attention to patients' overall well-being.
View Article and Find Full Text PDF